Illness Perception in Patients with Differentiated Epithelial Cell Thyroid Cancer

Hirsch, Dania; Ginat, Michal; Levy, Sigal; Benbassat, Carlos; Weinstein, Ruth; Tsvetov, Gloria; Singer, Joelle; Shraga-Slutzky, Ilana; Grozinski-Glasberg, Simona; Mansiterski, Yossi; Shimon, Ilan; Reicher-Atir, Rivka

doi:10.1089/thy.2008.0360

Cited by 57 publications

(49 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They recorded significantly lower QoL scores in DTC subjects than in controls, and found that prolonged follow-up in a disease-free condition was an important predictor of improvement in QoL. Using a validated perception questionnaire, Hirsch et al (2009) evaluated illness perception in a study group of 110 consecutive subjects with a history of DTC under routine follow-up. They found that subjects perceived their illness on a subjective and emotional basis and that a lower level of education, short time since the last treatment, disease persistence, and the number of iodine treatments were associated with QoL impairment.…”

Section: Introductionmentioning

confidence: 99%

“…In this study, we used self-rated questionnaires, both constructed ad hoc and previously well-validated in thyroid pathology (Giusti et al, 2005), and well-known instruments used extensively by thyroidologists (Billewicz et al, 1969) or psychiatrists (Hamilton, 1959;1960). The objectives of the study were: (1) to confirm the wide variation of illness perception (Crevenna et al, 2003;Hirsch et al, 2009) in DTC subjects, as already documented in the whole spectrum of thyroid pathologies (Bianchi et al, 2004;Miccoli et al, 2007), which, however, should require a new specific thyroid questionnaire (Watt et al, 2010); (2) to verify our previous impression (Giusti et al, 2005) that, in unselected DTC, periodic follow-up examinations and the use of less aggressive diagnostic/therapeutic methods (Lee et al, 2010) improve health-related QoL over time; (3) to demonstrate that the prolonged follow-up of DTC subjects normalizes QoL to the levels reported in subjects with benign post-surgical thyroid pathology.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma

Giusti

Melle

Fenocchio

et al. 2011

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Differentiated thyroid carcinoma (DTC) generally has a favorable outcome. Thyroid disease, treatments, stress, and comorbidity can compromise health-related quality of life (QoL) and indirectly weigh upon the outcome. From 2004 to 2008, we evaluated QoL longitudinally in 128 DTC subjects. During scheduled examinations, subjects were asked to undergo a semi-structured psychiatric interview and five rated inventories. The same examination was conducted in 219 subjects after surgery for benign thyroid pathology. Low scores represent a better QoL. DTC and control subjects were similar in terms of age, male/female ratio, concomitant psychopharmacological treatments, and frequency of psychiatric diseases. In DTC subjects, Billewicz scale (BS) scores showed an increasing trend over time, especially among females. The ad hoc thyroid questionnaire (TQ) scores were similar in both groups and did not change over time, but at the end of the study ad hoc TQ and BS were significantly related. Ad hoc TQ scores were also related to age on entry to the study. In both male and female DTC subjects, Hamilton's tests for anxiety (HAM-A), but not for depression (HAM-D), showed an improving trend. At the end of the study, HAM-A and HAM-D scores were comparable to those of the control group. HAM-A and HAM-D were both positively correlated with the stage of cancer and the time between diagnosis and treatment. Only HAM-D correlated with age on entry to the study. Kellner symptom questionnaire (KSQ) item scores were higher in DTC subjects than in controls. The change over time in the items including anxiety, somatization, depression, and hostility was significant. Somatization and hostility were more significantly reduced in DTC females than in DTC males. Hostility scores were significantly lower in DTC subjects than in controls at the end of the study. Somatization and depression were significantly related to staging on diagnosis and age on entry to the study. Our study confirms a wide variation of illness perception in DTC subjects, which is generally unrelated to the favorable clinical follow-up of the disease. Psychological evaluation during long-term follow-up improved QoL scores, which reached the same levels noted in subjects with a history of thyroid surgery for benign thyroid pathology. Our data indicate that special attention should be paid to QoL in older DTC subjects and those with more severe staging on diagnosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma

Giusti

Melle

Fenocchio

et al. 2011

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

show abstract

“…Fast et al (2014) found that the majority of patients treated with rhTSH for goitre reported an improvement in symptoms on the specific ThyPRO scale concerning goitre, and that the improvement persisted at least up to the 36 th month [19]. Moreover, according to studies conducted by two groups of surgeons on patients who had undergone thyroidectomy for goitre, QoL improved significantly after surgery, whether total thyroidectomy or hemithyroidectomy had been performed [24,25].…”

Section: Discussionmentioning

confidence: 99%

“…SF-36, Hamilton scale and the Kellner Symptoms Questionnaire). Questionnaires for QoL evaluation have been used in numerous benign and malignant thyroid diseases, such as benign goitre treated with RAI following rhTSH premedication, autoimmune hypothyroidism and chronic autoimmune thyroiditis [14][15][16][17][18][19][20][21][22][23] The "general score" of ThyPRO, which answers the question "In the last 4 weeks, has thyroid disease had a negative effect on your quality of life? ", improved from the 3rd month onwards.…”

Section: Discussionmentioning

confidence: 99%

Quality of life in patients treated with radiofrequency ablation for thyroid nodules

Oddo¹,

Felix²,

Repetto³

et al. 2016

Res J Endocrinol Metab

View full text Add to dashboard Cite

Background: Many studies have reported mean reductions in nodule volumes and described improvements in the sense of pressure and aesthetic symptoms after radiofrequency ablation. The aim of our study was to document changes in quality of life by means of a 13-scale questionnaire named ThyPRO in a cohort of patients treated with radiofrequency ablation for benign thyroid nodules. Moreover, we assessed the efficacy and safety of the procedure and correlations between efficacy and some features both of the treated nodules and of patients, and evaluated improvements in neck discomfort by means of a visual analogic scale. Methods: 32 patients with benign thyroid nodules were treated with radiofrequency ablation. We evaluated nodule volume, thyroid function and autoimmunity before and after procedures, adverse events during and after procedures, changes in neck discomfort by means of a visual analogic scale and changes in quality of life through the ThyPRO questionnaire at 1, 3, 6 12, 24 and 36 months. We sought correlations between response to radiofrequency ablation and some features of procedures and patients. We divided patients into 2 groups, according to their mean percentage of nodule volume reduction: group 1 (reduction >30%) and group 2 (reduction <30%) to evaluate whether ThyPRO questionnaire scores changed in patients in whom thyroid RFA was more effective. Results: At the last evaluation, nodule volume reduction was 45±9 in group 1, 11±9 in group 2 and 40±25% in the total population. We found a correlation between better volume reduction and greater patient age. Thyroid function and autoimmunity were not modified. Adverse events were few and mild. Visual analogic scale scores improved, though scores on the individual ThyPRO scales did not change, even in group 1. The general subjective impact of thyroid disease on quality of life improved from the 3rd month onwards. Conclusions: In our cohort of patients, quality of life, as evaluated through ThyPRO, did not improve after radiofrequency for benign thyroid nodules. In the literature, changes in quality of life in patients treated with radiofrequency ablation for thyroid nodules have been described in only one paper, while changes in quality of life assessed by means of ThyPRO have never been described.

show abstract

“…While it is important to detect recurrences in an early stage it should be taken into account that the quality of life of patients with DTC could be diminished by the type and number of investigations during follow-up. It has been shown that patients perceive their illness on an emotional basis unrelated to its actual severity and cancer stage [6]. An important factor in the follow-up of DTC patients, therefore, is to detect recurrent disease without 'over-investigating' these patients.…”

Section: Discussionmentioning

confidence: 99%

High Negative Predictive Value (NPV) Of Undetectable TSH Stimulated Tg For Disease Recurrence In Both Low And High Risk Differentiated Thyroid Cancer

Meer¹,

Vriens²,

Valk³

et al. 2014

Thyroid Disorders Ther

View full text Add to dashboard Cite

Illness Perception in Patients with Differentiated Epithelial Cell Thyroid Cancer

Cited by 57 publications

References 27 publications

Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma

Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma

Quality of life in patients treated with radiofrequency ablation for thyroid nodules

High Negative Predictive Value (NPV) Of Undetectable TSH Stimulated Tg For Disease Recurrence In Both Low And High Risk Differentiated Thyroid Cancer

Contact Info

Product

Resources

About